Cargando…

Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis

Autologous hematopoietic stem cell transplantation (AHSCT) has been approved for multiple sclerosis (MS) in many European countries. A large proportion of patients are women of child-bearing age. For them, AHSCT may have negative consequences for reproductive health, since the ovaries are particular...

Descripción completa

Detalles Bibliográficos
Autores principales: Zafeiri, Lida, Åkerfeldt, Torbjörn, Tolf, Andreas, Carlson, Kristina, Skalkidou, Alkistis, Burman, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096464/
https://www.ncbi.nlm.nih.gov/pubmed/37043510
http://dx.doi.org/10.1371/journal.pone.0284288
_version_ 1785024342666510336
author Zafeiri, Lida
Åkerfeldt, Torbjörn
Tolf, Andreas
Carlson, Kristina
Skalkidou, Alkistis
Burman, Joachim
author_facet Zafeiri, Lida
Åkerfeldt, Torbjörn
Tolf, Andreas
Carlson, Kristina
Skalkidou, Alkistis
Burman, Joachim
author_sort Zafeiri, Lida
collection PubMed
description Autologous hematopoietic stem cell transplantation (AHSCT) has been approved for multiple sclerosis (MS) in many European countries. A large proportion of patients are women of child-bearing age. For them, AHSCT may have negative consequences for reproductive health, since the ovaries are particularly susceptible to alkylating agents. Anti-Müllerian hormone (AMH) reflects the ovarian reserve and has been suggested as a potential biomarker of fertility in women. The aim of this study was to investigate AMH levels in relation to age and reproductive potential in MS patients treated with AHSCT. The study cohort comprised 38 female patients, aged 20–44 years, who underwent AHSCT for MS using a cyclophosphamide (200 mg/kg)/rabbit—anti-thymocyte globulin (6 mg/kg) conditioning regimen between 2013–2020. Clinal follow-up visits were made 3 months after AHSCT and then yearly. AMH was analysed in blood samples. The median age at transplantation was 28 years (interquartile range, IQR 25–33). The median AMH concentration was 23 pmol/l at baseline (IQR 6.0–30), 0.5 pmol/l at 3 months (IQR 0–1.5) and 1.1 pmol/l at 2 years (IQR 0–2.9). A multiple linear regression model was used to determine if age and/or AHSCT influenced AMH values; both significantly did (age, -0.21 per year, p = 0.018; AHSCT -19, p <0.0001). Seven women became pregnant, six spontaneously and one both spontaneously and with IVF. One patient underwent an abortion, all other pregnancies led to live births. Six of the women became pregnant despite low or very low post-AHSCT serum concentrations of AMH, suggesting that low serum AMH concentrations do not necessarily reflect impaired fertility in patients treated with high-dose cyclophosphamide.
format Online
Article
Text
id pubmed-10096464
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-100964642023-04-13 Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis Zafeiri, Lida Åkerfeldt, Torbjörn Tolf, Andreas Carlson, Kristina Skalkidou, Alkistis Burman, Joachim PLoS One Research Article Autologous hematopoietic stem cell transplantation (AHSCT) has been approved for multiple sclerosis (MS) in many European countries. A large proportion of patients are women of child-bearing age. For them, AHSCT may have negative consequences for reproductive health, since the ovaries are particularly susceptible to alkylating agents. Anti-Müllerian hormone (AMH) reflects the ovarian reserve and has been suggested as a potential biomarker of fertility in women. The aim of this study was to investigate AMH levels in relation to age and reproductive potential in MS patients treated with AHSCT. The study cohort comprised 38 female patients, aged 20–44 years, who underwent AHSCT for MS using a cyclophosphamide (200 mg/kg)/rabbit—anti-thymocyte globulin (6 mg/kg) conditioning regimen between 2013–2020. Clinal follow-up visits were made 3 months after AHSCT and then yearly. AMH was analysed in blood samples. The median age at transplantation was 28 years (interquartile range, IQR 25–33). The median AMH concentration was 23 pmol/l at baseline (IQR 6.0–30), 0.5 pmol/l at 3 months (IQR 0–1.5) and 1.1 pmol/l at 2 years (IQR 0–2.9). A multiple linear regression model was used to determine if age and/or AHSCT influenced AMH values; both significantly did (age, -0.21 per year, p = 0.018; AHSCT -19, p <0.0001). Seven women became pregnant, six spontaneously and one both spontaneously and with IVF. One patient underwent an abortion, all other pregnancies led to live births. Six of the women became pregnant despite low or very low post-AHSCT serum concentrations of AMH, suggesting that low serum AMH concentrations do not necessarily reflect impaired fertility in patients treated with high-dose cyclophosphamide. Public Library of Science 2023-04-12 /pmc/articles/PMC10096464/ /pubmed/37043510 http://dx.doi.org/10.1371/journal.pone.0284288 Text en © 2023 Zafeiri et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Zafeiri, Lida
Åkerfeldt, Torbjörn
Tolf, Andreas
Carlson, Kristina
Skalkidou, Alkistis
Burman, Joachim
Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis
title Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis
title_full Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis
title_fullStr Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis
title_full_unstemmed Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis
title_short Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis
title_sort anti-müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096464/
https://www.ncbi.nlm.nih.gov/pubmed/37043510
http://dx.doi.org/10.1371/journal.pone.0284288
work_keys_str_mv AT zafeirilida antimullerianhormoneandpregnancyafterautologoushematopoieticstemcelltransplantationformultiplesclerosis
AT akerfeldttorbjorn antimullerianhormoneandpregnancyafterautologoushematopoieticstemcelltransplantationformultiplesclerosis
AT tolfandreas antimullerianhormoneandpregnancyafterautologoushematopoieticstemcelltransplantationformultiplesclerosis
AT carlsonkristina antimullerianhormoneandpregnancyafterautologoushematopoieticstemcelltransplantationformultiplesclerosis
AT skalkidoualkistis antimullerianhormoneandpregnancyafterautologoushematopoieticstemcelltransplantationformultiplesclerosis
AT burmanjoachim antimullerianhormoneandpregnancyafterautologoushematopoieticstemcelltransplantationformultiplesclerosis